Researchers have looked at a sample population of senior adults newly diagnosed with wet age-related macular degeneration (exudative, or neovascular, AMD) and found that those who received either Lucentis or Avastin injections* were 19% less likely to be admitted to a long-term care facility during the follow-up period. The reason? The introduction of anti-VEGF therapy reduced vision loss by 41% and onset of severe vision loss and blindness by 46%.
*Eylea had not yet been approved at the time of this study.
Source: The Effects of Technological Advances on Outcomes for Elderly Persons With Exudative Age-related Macular Degeneration. Frank A. Sloan, PhD; Brian W. Hanrahan, MA (JAMA Ophthalmol. Published online January 23, 2014. doi:10.1001/jamaophthalmol.2013.7647)
